Page last updated: 2024-11-13

fr 264205

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

ceftolozane: cephalosporin anti-bacterial agent with enhanced activity against Pseudomonas aeruginosa [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ceftolozane : A fifth-generation cephalosporin antibiotic having (5-amino-4-{[(2-aminoethyl)carbamoyl]amino}-1-methyl-1H-pyrazol-2-ium-2-yl)methyl and [(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino side groups located at positions 3 and 7 respectively; developed for the treatment of infections with gram-negative bacteria that have become resistant to conventional antibiotics. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID52918380
MeSH IDM0509526

Synonyms (27)

Synonym
fr-264205
cxa-101
ceftolozane
cxa-301
936111-69-2
ceftolozane sulfate (jan/usan)
D10098
1h-pyrazolium, 5-amino-4-((((2-aminoethyl)amino)carbonyl)amino)-2-(((6r,7r)-7-(((2z)- 2-(5-amino-1,2,4-thiadiazol-3-yl)-2-((1-carboxy-1-methylethoxy)imino)acetyl)amino)-2- carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-1-methyl-, sulfate (1
ceftolozane sulfate [usan]
5-amino-4-(((2-aminoethyl)carbamoyl)amino)-2-(((6r,7r)-7-(((2z)-2-(5-amino-1,2,4- thiadiazol-3-yl)-2-((1-carboxy-1-methylethoxy)imino)acetyl)amino)-2-carboxy-8-oxo-5- thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-1-methyl-1h-pyrazolium monosulfate
unii-7r247u84hy
7r247u84hy ,
fr 264205
cxa 101
ceftolozane sulfate [mi]
ceftolozane sulfate [vandf]
zerbaxa component ceftolozane sulfate
5-amino-4-(((2-aminoethyl)carbamoyl)amino)-2-(((6r,7r)-7-(((2z)-2-(5-amino-1,2,4- thiadiazol-3-yl)-2-((1-carboxy-1-methylethoxy)imino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-1-methyl-1h-pyrazolium monosulfate
ceftolozane sulfate [who-dd]
ceftolozane sulfate [jan]
ceftolozane sulfate component of zerbaxa
ceftolozane sulfate [orange book]
EX-A4483
(6r,7r)-3-[[3-amino-4-(2-aminoethylcarbamoylamino)-2-methylpyrazol-1-ium-1-yl]methyl]-7-[[(2z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydrogen sulfate
DTXSID001027693
AC-36560
AKOS040751070

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Drug-related systemic adverse events were infrequent and mild."( Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions.
Friedland, I; Ge, Y; Talbot, GH; Whitehouse, MJ, 2010
)
0.36
" There were no deaths or adverse event-related study discontinuations."( Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia.
Adedoyin, A; Caro, L; De Waele, JJ; Gadzicki, E; Kuti, JL; Larson, KB; Nicolau, DP; Rhee, EG; Yu, B; Zeng, Z, 2020
)
0.56
" Secondary endpoints included clinical and microbiologic responses at the TOC and end-of-treatment (≤24 hours after last dose) visits and adverse event rates."( A phase III, multicenter, double-blind, randomized clinical trial to evaluate the efficacy and safety of ceftolozane/tazobactam plus metronidazole versus meropenem in Chinese participants with complicated intra-abdominal infections.
Bensaci, M; Bruno, CJ; Chen, G; Chen, X; Du, X; Fan, J; Huntington, JA; Johnson, MG; Sun, F; Sun, Y; Wang, H; Wang, Y, 2022
)
0.72
" Rates of adverse events were similar between treatment groups (any: ceftolozane/tazobactam, 59."( Safety and Efficacy of Ceftolozane/Tazobactam Versus Meropenem in Neonates and Children With Complicated Urinary Tract Infection, Including Pyelonephritis: A Phase 2, Randomized Clinical Trial.
Ashouri, N; Bensaci, M; Bradley, JS; Bruno, CJ; De Anda, C; Huntington, JA; Johnson, MG; Lonchar, J; Popejoy, MW; Rhee, EG; Roilides, E; Su, FH, 2023
)
0.91
" Ceftolozane/tazobactam is a safe and effective new treatment option for children with cUTI, especially due to antibacterial-resistant Gram-negative pathogens."( Safety and Efficacy of Ceftolozane/Tazobactam Versus Meropenem in Neonates and Children With Complicated Urinary Tract Infection, Including Pyelonephritis: A Phase 2, Randomized Clinical Trial.
Ashouri, N; Bensaci, M; Bradley, JS; Bruno, CJ; De Anda, C; Huntington, JA; Johnson, MG; Lonchar, J; Popejoy, MW; Rhee, EG; Roilides, E; Su, FH, 2023
)
0.91
" Adverse events (AEs) occurred in 80."( Safety and Efficacy of Ceftolozane/Tazobactam Plus Metronidazole Versus Meropenem From a Phase 2, Randomized Clinical Trial in Pediatric Participants With Complicated Intra-abdominal Infection.
Bensaci, M; Bruno, CJ; De Anda, C; Dementieva, N; Huntington, JA; Jackson, CA; Johnson, MG; Lonchar, J; Newland, J; Popejoy, MW; Rhee, EG; Su, FH, 2023
)
0.91
" Statistically significant trends were observed favoring cefotaxime plus metronidazole, which exhibited fewer discontinuations because of adverse events (AEs) when compared with eravacycline, meropenem and ceftolozane/tazobactam plus metronidazole (OR = 0."( Efficacy, safety, and tolerability of antimicrobial agents for complicated intra-abdominal infection: a systematic review and network meta-analysis.
Deng, T; Kong, W; Li, S; Shu, Y; Wu, Y, 2023
)
0.91
"This observational study demonstrated that TAZ/CTLZ in combination with metronidazole has a favorable effect without major drug-related adverse events for intraabdominal infection in the hepato-biliary-pancreatic field in clinical practice although the efficacy of TAZ/CTLZ may decrease in compromised patients."( Efficacy and safety of tazobactam/ceftolozane in combination with metronidazole for intraabdominal infection in a hepato-biliary-pancreatic field in clinical practice.
Ishizawa, T; Kimura, K; Kinoshita, M; Kubo, S; Nishio, K; Ohira, G; Okada, T; Shinkawa, H; Shirai, D; Tanaka, S; Tani, N; Tauchi, J, 2023
)
0.91

Pharmacokinetics

ExcerptReferenceRelevance
" Blood and urine pharmacokinetic samples were assayed by a validated bioanalytical method and analyzed using standard noncompartmental methodology."( Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions.
Friedland, I; Ge, Y; Talbot, GH; Whitehouse, MJ, 2010
)
0.36
" Serum concentration data from 376 adults who received ceftolozane/tazobactam in doses ranging from 500 to 3000 mg were analyzed to identify factors contributing to the pharmacokinetic variability."( Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections.
Chandorkar, G; Hershberger, E; Krishna, G; Mouksassi, MS; Xiao, A, 2015
)
0.42
" Surprisingly, although tazobactam has been available for over 20 years, few if any reliable data exist on the tazobactam pharmacokinetic (PK) properties in mice."( Plasma and epithelial lining fluid pharmacokinetics of ceftolozane and tazobactam alone and in combination in mice.
Lagarde, C; Mavridou, E; Melchers, MJ; Mouton, JW; Seyedmousavi, S; van Mil, AC, 2015
)
0.42
" A population pharmacokinetic (PK) model with the plasma-to-epithelial lining fluid (ELF) kinetics of ceftolozane/tazobactam was used to justify dosing regimens for patients with nosocomial pneumonia in phase 3 studies."( Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia.
Huntington, JA; Miller, BW; Nicolau, DP; Xiao, AJ, 2016
)
0.43
" In this study, we studied the pharmacodynamics of ceftolozane plus tazobactam against Escherichia coli and Pseudomonas aeruginosa using an in vitro pharmacokinetic model of infection."( Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of Infection.
Bowker, KE; MacGowan, AP; Nicholls, D; Noel, AR; Tomaselli, SG, 2016
)
0.43
"63 μg/ml, time to Cmax (Tmax) of 4 h, area under the concentration-time curve from 0 to 8 h (AUC0-8) of 284."( Ceftolozane-Tazobactam Pharmacokinetics in a Critically Ill Patient on Continuous Venovenous Hemofiltration.
Gonzales, JP; Heil, EL; Mehrotra, S; Nicolau, DP; Oliver, WD; Robinett, K; Saleeb, P, 2015
)
0.42
" Monte Carlo simulations (MCS) using pharmacokinetic parameters from published studies and CLTM from this study were used to generate ceftolozane/tazobactam dosing for patients receiving CRRT."( Ex vivo Ceftolozane/Tazobactam Clearance during Continuous Renal Replacement Therapy.
Chaijamorn, W; Lewis, SJ; Mueller, BA; Shaw, AR, 2017
)
0.46
" MCS-derived ceftolozane/tazobactam doses of 750 (500/250)-1,500 (1,000/500) mg every 8 h met pharmacodynamic targets for virtual patients receiving CRRT at contemporary effluent rates."( Ex vivo Ceftolozane/Tazobactam Clearance during Continuous Renal Replacement Therapy.
Chaijamorn, W; Lewis, SJ; Mueller, BA; Shaw, AR, 2017
)
0.46
" Pharmacokinetic parameters were estimated by non-compartmental analysis and pharmacodynamic analyses were conducted to graphically evaluate achievement of target exposures (plasma and ELF ceftolozane concentrations >4 mg/L and tazobactam concentrations >1 mg/L; target in plasma: ≥30% and ≥20% of the dosing interval, respectively)."( Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia.
Adedoyin, A; Caro, L; De Waele, JJ; Gadzicki, E; Kuti, JL; Larson, KB; Nicolau, DP; Rhee, EG; Yu, B; Zeng, Z, 2020
)
0.56
" Ceftolozane and tazobactam Tmax (6 and 2 h, respectively) were delayed in ELF compared with plasma (1 h)."( Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia.
Adedoyin, A; Caro, L; De Waele, JJ; Gadzicki, E; Kuti, JL; Larson, KB; Nicolau, DP; Rhee, EG; Yu, B; Zeng, Z, 2020
)
0.56
" Pharmacokinetic analysis of in vivo data (non-compartmental analysis and non-linear mixed effects modelling) was performed to determine the influence of ECMO."( Influence of extracorporeal membrane oxygenation on the pharmacokinetics of ceftolozane/tazobactam: an ex vivo and in vivo study.
Concordet, D; Delmas, C; Gandia, P; Georges, B; Jourdan, G; Mané, C; Marcheix, B; Porterie, J; Ruiz, S; Verwaerde, P, 2020
)
0.56
" In vivo pharmacokinetic exploration showed that ECMO induces a significant decrease of 37% for tazobactam clearance without significant modification in the pharmacokinetics of ceftolozane, probably due to a small cohort size."( Influence of extracorporeal membrane oxygenation on the pharmacokinetics of ceftolozane/tazobactam: an ex vivo and in vivo study.
Concordet, D; Delmas, C; Gandia, P; Georges, B; Jourdan, G; Mané, C; Marcheix, B; Porterie, J; Ruiz, S; Verwaerde, P, 2020
)
0.56
"This methodology was successfully applied to one pilot pharmacokinetic study in infected critically ill patients, including patients receiving renal replacement therapy, and one case study of a patient with ventriculitis, where all patients received ceftolozane-tazobactam."( A validated LC-MS/MS method for the simultaneous quantification of the novel combination antibiotic, ceftolozane-tazobactam, in plasma (total and unbound), CSF, urine and renal replacement therapy effluent: application to pilot pharmacokinetic studies.
Lipman, J; Pandey, S; Parker, SL; Roberts, JA; Sime, FB; Stuart, J; Wallis, SC, 2021
)
0.62
" Steady state free ceftolozane plasma Cmax and Cmin concentrations were calculated to be 122."( Ceftolozane/tazobactam for refractory P. aeruginosa endocarditis: A case report and pharmacokinetic analysis.
Bremmer, DN; Kline, EG; Nicolau, DP; Shah, S; Shields, RK, 2022
)
0.72
"To use a pre-clinical pharmacokinetic infection model to assess the antibacterial effect of ceftolozane/tazobactam alone or in combination with fosfomycin or tobramycin against Pseudomonas aeruginosa strains with MICs at or higher than the clinical breakpoint (MIC ≥ 4 mg/L)."( Antibacterial effect of seven days exposure to ceftolozane-tazobactam as monotherapy and in combination with fosfomycin or tobramycin against Pseudomonas aeruginosa with ceftolozane-tazobactam MICs at or above 4 mg/l in an in vitro pharmacokinetic model.
Albur, M; Attwood, M; Griffin, P; Macgowan, AP; Noel, AR, 2023
)
0.91

Compound-Compound Interactions

ExcerptReferenceRelevance
"CXA-101, a novel oxyimino-aminothiazolyl cephalosporin, CXA-201 (CXA-101 combined with tazobactam), and various comparators were susceptibility tested by broth microdilution methods against 1,301 well-characterized clinical strains collected worldwide, including ceftazidime-resistant members of the family Enterobacteriaceae and Klebsiella pneumoniae carbapenemase (KPC)- and extended-spectrum β-lactamase (ESBL)-producing strains of Pseudomonas aeruginosa and Bacteroides fragilis."( Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes.
Farrell, DJ; Jones, RN; Rhomberg, PR; Sader, HS, 2011
)
0.37
"We recently investigated the pharmacokinetics-pharmacodynamics (PK-PD) of tazobactam in combination with ceftolozane against an isogenic CTX-M-15-producing Escherichia coli triplet set, genetically engineered to transcribe different levels of blaCTX-M-15."( Pharmacological basis of β-lactamase inhibitor therapeutics: tazobactam in combination with Ceftolozane.
Ambrose, PG; Bhavnani, SM; Bulik, CC; Forrest, A; Friedrich, LV; Jones, RN; McCauley, J; Mendes, RE; Okusanya, OO; Steenbergen, JN; Vanscoy, B, 2013
)
0.39
"The post-β-lactamase-inhibitor effect (PBLIE) of tazobactam combined with ceftolozane was evaluated by time-kill assays on two clinical Escherichia coli strains producing CTX-M-15 with or without TEM-1."( Post-β-lactamase-inhibitor effect of tazobactam in combination with ceftolozane on extended-spectrum-β-lactamase-producing strains.
Jones, RN; Rhomberg, PR; Sader, HS, 2014
)
0.4
" When combined with a fixed amount of 4 mg/liter tazobactam (current CLSI concentration used for susceptibility testing), 90% of the isolates would have an MIC of ≤4 mg/liter."( In Vitro Activity of Ceftolozane Alone and in Combination with Tazobactam against Extended-Spectrum-β-Lactamase-Harboring Enterobacteriaceae.
Melchers, MJ; Mouton, JW; van Mil, AC, 2015
)
0.42
" This study evaluated in vitro antimicrobial synergy of ceftolozane/tazobactam in combination with aztreonam and fosfomycin against MDR PSA."( In vitro synergy of ceftolozane/tazobactam in combination with fosfomycin or aztreonam against MDR Pseudomonas aeruginosa.
Cayô, R; Cuba, GT; Gales, AC; Kiffer, CRV; Nicolau, DP; Nodari, CS; Pignatari, ACC; Rocha-Santos, G; Streling, AP, 2020
)
0.56
"5 g q8h dose, respectively, in combination with 69 mg/L amikacin, corresponding to the free peak plasma concentration."( In vitro activity of ceftolozane/tazobactam alone and in combination with amikacin against MDR/XDR Pseudomonas aeruginosa isolates from Greece.
Adamou, P; Antoniadou, A; Damala, M; Deliolanis, I; Fountoulis, K; Galani, I; Galani, L; Giamarellou, H; Karaiskos, I; Karantani, I; Kirikou, H; Kodonaki, A; Maraki, S; Markopoulou, M; Papadogeorgaki, E; Papoutsaki, V; Petinaki, E; Prifti, E; Souli, M; Tsiplakou, S; Vagiakou, E, 2020
)
0.56
" In combination with amikacin, a synergistic interaction at 24 h was observed against 85."( In vitro activity of ceftolozane/tazobactam alone and in combination with amikacin against MDR/XDR Pseudomonas aeruginosa isolates from Greece.
Adamou, P; Antoniadou, A; Damala, M; Deliolanis, I; Fountoulis, K; Galani, I; Galani, L; Giamarellou, H; Karaiskos, I; Karantani, I; Kirikou, H; Kodonaki, A; Maraki, S; Markopoulou, M; Papadogeorgaki, E; Papoutsaki, V; Petinaki, E; Prifti, E; Souli, M; Tsiplakou, S; Vagiakou, E, 2020
)
0.56
"Vancomycin (VAN)-associated acute kidney injury (AKI) is increased when VAN is combined with certain beta-lactams (BLs) such as piperacillin-tazobactam (TZP) but has not been evaluated with ceftolozane-tazobactam (C/T)."( Nephrotoxicity of Vancomycin in Combination With Beta-Lactam Agents: Ceftolozane-Tazobactam vs Piperacillin-Tazobactam.
Alosaimy, S; Amaya, L; Biagi, M; Chandler, E; Cubillos, A; Davis, SL; Finch, N; Hobbs, ALV; Holger, D; Jorgensen, SCJ; Kufel, WD; Kunz Coyne, AJ; Lagnf, AM; Li, D; Molina, KC; Moore, WJ; Morrisette, T; Mubarez, M; Patch, M; Polisetty, RS; Rebold, N; Rico, M; Rybak, MJ; Sakoulas, G; Simon, SP; Smith, IMK; Tran, NN; Truong, J; Venugopalan, V; Veve, MP; Witucki, P; Wrin, J; Yost, C, 2023
)
0.91
"This single-center study evaluated the efficacy and safety of tazobactam/ceftolozane (TAZ/CTLZ) in combination with metronidazole for intraabdominal infection in a hepato-biliary-pancreatic field in clinical practice."( Efficacy and safety of tazobactam/ceftolozane in combination with metronidazole for intraabdominal infection in a hepato-biliary-pancreatic field in clinical practice.
Ishizawa, T; Kimura, K; Kinoshita, M; Kubo, S; Nishio, K; Ohira, G; Okada, T; Shinkawa, H; Shirai, D; Tanaka, S; Tani, N; Tauchi, J, 2023
)
0.91
"This observational study demonstrated that TAZ/CTLZ in combination with metronidazole has a favorable effect without major drug-related adverse events for intraabdominal infection in the hepato-biliary-pancreatic field in clinical practice although the efficacy of TAZ/CTLZ may decrease in compromised patients."( Efficacy and safety of tazobactam/ceftolozane in combination with metronidazole for intraabdominal infection in a hepato-biliary-pancreatic field in clinical practice.
Ishizawa, T; Kimura, K; Kinoshita, M; Kubo, S; Nishio, K; Ohira, G; Okada, T; Shinkawa, H; Shirai, D; Tanaka, S; Tani, N; Tauchi, J, 2023
)
0.91
"To use a pre-clinical pharmacokinetic infection model to assess the antibacterial effect of ceftolozane/tazobactam alone or in combination with fosfomycin or tobramycin against Pseudomonas aeruginosa strains with MICs at or higher than the clinical breakpoint (MIC ≥ 4 mg/L)."( Antibacterial effect of seven days exposure to ceftolozane-tazobactam as monotherapy and in combination with fosfomycin or tobramycin against Pseudomonas aeruginosa with ceftolozane-tazobactam MICs at or above 4 mg/l in an in vitro pharmacokinetic model.
Albur, M; Attwood, M; Griffin, P; Macgowan, AP; Noel, AR, 2023
)
0.91

Dosage Studied

ExcerptRelevanceReference
" In part 2, cohorts 1 and 2 received 500 mg and 1,000 mg, respectively, every 8 h, and cohort 3 received 1,500 mg every 12 h; each cohort received dosing for 10 days."( Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions.
Friedland, I; Ge, Y; Talbot, GH; Whitehouse, MJ, 2010
)
0.36
" The percentage of the dosing interval that tazobactam concentrations remained above a threshold (%Time>threshold) was identified as the PK-PD exposure measure that was most closely associated with efficacy."( Pharmacological basis of β-lactamase inhibitor therapeutics: tazobactam in combination with Ceftolozane.
Ambrose, PG; Bhavnani, SM; Bulik, CC; Forrest, A; Friedrich, LV; Jones, RN; McCauley, J; Mendes, RE; Okusanya, OO; Steenbergen, JN; Vanscoy, B, 2013
)
0.39
" The experiment duration was 10 days, and the ceftolozane-tazobactam dose ratio (2:1) and dosing interval (every 8 h) were selected to approximate those expected to be used clinically."( Relationship between ceftolozane-tazobactam exposure and selection for Pseudomonas aeruginosa resistance in a hollow-fiber infection model.
Ambrose, PG; Bhavnani, SM; Castanheira, M; Friedrich, LV; Jones, RN; McCauley, J; Mendes, RE; Steenbergen, JN; VanScoy, BD, 2014
)
0.4
" A population pharmacokinetic (PK) model with the plasma-to-epithelial lining fluid (ELF) kinetics of ceftolozane/tazobactam was used to justify dosing regimens for patients with nosocomial pneumonia in phase 3 studies."( Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia.
Huntington, JA; Miller, BW; Nicolau, DP; Xiao, AJ, 2016
)
0.43
" Its dosing and chemistry provide expansive antimicrobial coverage of gram-negative organisms, including Pseudomonas aeruginosa, and stable activity against many β-lactamases, as well as coverage of most extended-spectrum β-lactamase-producing organisms and some anaerobes."( Ceftolozane-tazobactam: A new-generation cephalosporin.
Cluck, D; Lewis, P; Moorman, J; Spivey, J; Stayer, B, 2015
)
0.42
"57 μg/ml, concentration at the end of the dosing interval (Cmin) of 31."( Ceftolozane-Tazobactam Pharmacokinetics in a Critically Ill Patient on Continuous Venovenous Hemofiltration.
Gonzales, JP; Heil, EL; Mehrotra, S; Nicolau, DP; Oliver, WD; Robinett, K; Saleeb, P, 2015
)
0.42
" Both ceftolozane/tazobactam and ceftazidime/avibactam are only available as intravenous formulations and are dosed 3 times daily in patients with normal renal function."( Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations.
Bonomo, RA; van Duin, D, 2016
)
0.43
"To determine ceftolozane/tazobactam transmembrane clearances (CLTM) in continuous hemofiltration (CHF) and continuous hemodialysis (CHD) and to determine optimal ceftolozane/tazobactam dosing regimens for patients receiving continuous renal replacement therapy (CRRT)."( Ex vivo Ceftolozane/Tazobactam Clearance during Continuous Renal Replacement Therapy.
Chaijamorn, W; Lewis, SJ; Mueller, BA; Shaw, AR, 2017
)
0.46
" Monte Carlo simulations (MCS) using pharmacokinetic parameters from published studies and CLTM from this study were used to generate ceftolozane/tazobactam dosing for patients receiving CRRT."( Ex vivo Ceftolozane/Tazobactam Clearance during Continuous Renal Replacement Therapy.
Chaijamorn, W; Lewis, SJ; Mueller, BA; Shaw, AR, 2017
)
0.46
"Prolonged intermittent renal replacement therapy (PIRRT) eliminates many drugs, and without dosing data, for new antibiotics like ceftolozane/tazobactam, suboptimal concentrations and treatment failure are likely."( Pharmacokinetics of Ceftolozane-Tazobactam during Prolonged Intermittent Renal Replacement Therapy.
Cheng, V; Dyer, J; Ingram, P; McWhinney, BC; Raby, E; Rawlins, M; Regli, A; Roberts, JA; Ungerer, JPJ, 2018
)
0.48
"A ceftolozane/tazobactam dose of 500 mg/250 mg appears to be sufficient to attain pharmacokinetic/pharmacodynamic targets during PIRRT while the manufacturer's recommended dosing of 100 mg/50 mg every 8 h was sufficient during non-PIRRT periods."( Pharmacokinetics of Ceftolozane-Tazobactam during Prolonged Intermittent Renal Replacement Therapy.
Cheng, V; Dyer, J; Ingram, P; McWhinney, BC; Raby, E; Rawlins, M; Regli, A; Roberts, JA; Ungerer, JPJ, 2018
)
0.48
" High-dose vitamin C was defined as a dosage in excess of 10 g or 24 g within 2 days of admission."( Effect of high-dose vitamin C therapy on severe burn patients: a nationwide cohort study.
Aso, S; Fushimi, K; Goto, H; Kaita, Y; Kojiro, M; Matsui, H; Nakajima, M; Yamaguchi, Y; Yasunaga, H, 2019
)
0.51
" Pharmacokinetic parameters were estimated by non-compartmental analysis and pharmacodynamic analyses were conducted to graphically evaluate achievement of target exposures (plasma and ELF ceftolozane concentrations >4 mg/L and tazobactam concentrations >1 mg/L; target in plasma: ≥30% and ≥20% of the dosing interval, respectively)."( Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia.
Adedoyin, A; Caro, L; De Waele, JJ; Gadzicki, E; Kuti, JL; Larson, KB; Nicolau, DP; Rhee, EG; Yu, B; Zeng, Z, 2020
)
0.56
" Mean ceftolozane and tazobactam ELF concentrations remained >4 mg/L and >1 mg/L, respectively, for 100% of the dosing interval."( Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia.
Adedoyin, A; Caro, L; De Waele, JJ; Gadzicki, E; Kuti, JL; Larson, KB; Nicolau, DP; Rhee, EG; Yu, B; Zeng, Z, 2020
)
0.56
"Considering that the influence of ECMO on the pharmacokinetics of ceftolozane/tazobactam is not clinically significant, normal ceftolozane and tazobactam dosing in critically ill patients should be effective for patients undergoing ECMO."( Influence of extracorporeal membrane oxygenation on the pharmacokinetics of ceftolozane/tazobactam: an ex vivo and in vivo study.
Concordet, D; Delmas, C; Gandia, P; Georges, B; Jourdan, G; Mané, C; Marcheix, B; Porterie, J; Ruiz, S; Verwaerde, P, 2020
)
0.56
" Higher dosing regimens coupled with continuous/extended infusion may be required in the case of higher CRRT intensity, deep-seated infections or poorly susceptible isolates."( Ceftolozane/tazobactam exposure in critically ill patients undergoing continuous renal replacement therapy: a PK/PD approach to tailor dosing.
De Ponti, F; Gatti, M; Giannella, M; Raschi, E; Viale, P, 2021
)
0.62
" The dosage regimen was customised in all patients based on creatinine clearance."( Real-life experience with ceftolozane/tazobactam in Canada: results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registry.
Ariano, R; Bassetti, M; Baxter, M; Borgia, S; Cervera, C; Dhami, R; Dow, G; Dube, M; Irfan, N; Karlowsky, JA; Kosar, J; Savoie, M; Tessier, JF; Walkty, A; Zhanel, GG; Zvonar, R, 2021
)
0.62
" Application of recommended dosages in patients with renal impairment requires the use of fractions of the full dose, as only one dosage is available for both antibiotics."( Pharmacokinetic/Pharmacodynamic Simulations of Cost-Effective Dosage Regimens of Ceftolozane-Tazobactam and Ceftazidime-Avibactam in Patients with Renal Impairment.
Bourguignon, L; Dheyriat, L; Ferry, T; Goutelle, S; Perpoint, T, 2022
)
0.72
" The molecule is time-dependent and stable when reconstituted at room temperature, facilitating safe and effective dosage optimization in frail and critically ill patients."( Ceftolozane-tazobactam in nosocomial pneumonia.
Candel, FJ; González Del Castillo, J; Julián Jiménez, A; Matesanz, M, 2022
)
0.72
" The pharmacokinetic/pharmacodynamic therapeutic target of C/T was defined as 100% of the duration of the dosing interval that free concentrations are above the minimum inhibitory concentration (MIC) (100 %ƒT ≥ MIC) of the causative pathogen."( Therapeutic Drug Monitoring and Prolonged Infusions of Ceftolozane/Tazobactam for MDR/XDR Pseudomonas aeruginosa Infections: An Observational Study.
Benítez-Cano, A; Grau, S; Luque, S; Navarrete-Rouco, ME; Roberts, JA; Sorlí, L, 2022
)
0.72
"The administration of C/T by prolonged infusion with TDM-guided dosing allowed the achievement of a pharmacokinetic/pharmacodynamic target even at lower doses."( Therapeutic Drug Monitoring and Prolonged Infusions of Ceftolozane/Tazobactam for MDR/XDR Pseudomonas aeruginosa Infections: An Observational Study.
Benítez-Cano, A; Grau, S; Luque, S; Navarrete-Rouco, ME; Roberts, JA; Sorlí, L, 2022
)
0.72
" A modeling/simulation approach was undertaken to inform optimal dosing in this population, using previously developed ceftolozane and tazobactam population pharmacokinetic models informed by data from 16 clinical studies."( Probability of Target Attainment Analyses to Inform Ceftolozane/Tazobactam Dosing Regimens for Patients With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia and End-Stage Renal Disease Receiving Intermittent Hemodialysis.
Bruno, CJ; De Anda, C; Feng, HP; Fiedler-Kelly, J; Gao, W; Patel, YT; Rhee, EG; Zhang, Z, 2023
)
0.91
"Probability of target attainment (PTA) analyses were conducted to support the recommended ceftolozane/tazobactam dosing regimens, adjusted for renal function, in patients with hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP)."( Ceftolozane/Tazobactam Probability of Target Attainment in Patients With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia.
Anda, C; Bruno, CJ; Feng, HP; Fiedler-Kelly, J; Gao, W; Johnson, MG; Patel, YT; Rhee, EG; Zhang, Z, 2023
)
0.91
"Ceftolozane-tazobactam (C/T) recommended dosing in patients undergoing renal replacement therapies (RRT) is lacking evidence."( Clinical outcomes of ceftolozane-tazobactam dosing in patients with sepsis undergoing renal replacement therapies.
Abidi, E; Al Ali, M; Attallah, N; El Lababidi, R; El Nekidy, WS; Ghazi, IM; Hijazi, F; Mallat, J, 2023
)
0.91
" Larger outcomes and pharmacokinetics studies are needed to establish effective dosing and therapy duration."( Clinical outcomes of ceftolozane-tazobactam dosing in patients with sepsis undergoing renal replacement therapies.
Abidi, E; Al Ali, M; Attallah, N; El Lababidi, R; El Nekidy, WS; Ghazi, IM; Hijazi, F; Mallat, J, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (197)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (2.54)29.6817
2010's76 (38.58)24.3611
2020's116 (58.88)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials17 (8.42%)5.53%
Reviews20 (9.90%)6.00%
Case Studies12 (5.94%)4.05%
Observational7 (3.47%)0.25%
Other146 (72.28%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]